Cautionary statement regarding forward-looking statementsUnder the safe harbor provisions of the U.S. Factors that could affect the Group’s operations are described in Risk Factors described in the Operating and Financial Review on and Prospects in the company Annual Report on Form 20-F for the year 2005 levitra lasts how long .

Molecule two U.S. Approval for Tykerb for the treatment of advanced breast cancerGlaxoSmithKline plc today announced the submission of a New Drug Application with the United States Food and Drug Administration for approval to market including Tykerb , in combination with Xeloda for the treatment of advanced or metastatic HER2 positive breast cancer in women who have received prior therapy Herceptin . The connection was fast track status from the U.S. FDA in this patient population. TYKERB is a small molecule, two kinase inhibitor developed by GSK as an oral therapy and is currently being studied in breast cancer and other solid tumors. TYKERB is an investigational compound and has not been approved for marketing by any regulatory authority. This proposal is the result of many years of tremendous research and development work by scientists at GSK It really is a major milestone, especially for the many thousands of women, who are facing the devastating effects of advanced breast cancer. Paolo Paoletti, Senior Vice President the Oncology Medicine Development Center at GSK said. Many of these women are in urgent need of alternative therapies, and this application shows round the corner round the corner towards a new era of targeted agents. .

On the Hear the early stages of research in search of genetic biomarkers for lung disease – similar way label found for heart disease. Without these highlighter, of the struggle against the lung sickness to continue decades after behind heart disease. Note and help us break the trend!

Courtesy They can enjoy the full Kaiser Daily HealthPolicyMonitor Report indicate looking for or sign or subscribe are released to e-mail infeed on the Emperor Daily Health policy coverage strongly committed emperor network. A free service of of The Henry Y. Kaiser Family foundatio 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Other articles from category "hypertension":

Random articles